scholarly journals A design for phase I trials in completely or partially ordered groups

2017 ◽  
Vol 36 (15) ◽  
pp. 2323-2332 ◽  
Author(s):  
Mark R. Conaway
2016 ◽  
Vol 36 (2) ◽  
pp. 254-265 ◽  
Author(s):  
Mark R. Conaway ◽  
Nolan A. Wages

2017 ◽  
Vol 14 (5) ◽  
pp. 491-498 ◽  
Author(s):  
Mark Conaway

Background/aims: Dose-finding trials can be conducted such that patients are first stratified into multiple risk groups before doses are allocated. The risk groups are often completely ordered in that, for a fixed dose, the probability of toxicity is monotonically increasing across groups. In some trials, the groups are only partially ordered. For example, one of several groups in a trial may be known to have the least risk of toxicity for a given dose, but the ordering of the risk among the remaining groups may not be known. The aim of the article is to introduce a method for designing dose-finding trials of cytotoxic agents in completely or partially ordered groups of patients. Methods: This article presents a method for dose-finding that combines previously proposed mathematical models, augmented with results using order restricted inference. The resulting method is computationally convenient and allows for dose-finding in trials with completely or partially ordered groups. Extensive simulations are done to evaluate the performance of the method, using randomly generated dose–toxicity curves where, within each group, the risk of toxicity is an increasing function of dose. Results: Our simulations show that the hybrid method, in which order-restricted estimation is applied to parameters of a parsimonious mathematical model, gives results that are similar to previously proposed methods for completely ordered groups. Our method generalizes to a wide range of partial orders among the groups. Conclusion: The problem of dose-finding in partially ordered groups has not been extensively studied in the statistical literature. The proposed method is computationally feasible, and provides a potential solution to the design of dose-finding studies in completely or partially ordered groups.


2011 ◽  
Vol 2 (3) ◽  
pp. 449-455 ◽  
Author(s):  
CHIARA CARLOMAGNO ◽  
GENNARO DANIELE ◽  
ROBERTO BIANCO ◽  
ROBERTA MARCIANO ◽  
VINCENZO DAMIANO ◽  
...  

1999 ◽  
Vol 35 ◽  
pp. S283
Author(s):  
C. Twelves ◽  
J.L. Misset ◽  
M. Villalona-Calero ◽  
D. Ryan ◽  
J. Clark ◽  
...  

1996 ◽  
Vol 7 (7) ◽  
pp. 728-733 ◽  
Author(s):  
Richard Pazdur ◽  
Yvonne Lassere ◽  
Enrique Diaz-Canton ◽  
Beth Bready ◽  
Dah H Ho

PLoS ONE ◽  
2012 ◽  
Vol 7 (12) ◽  
pp. e51039 ◽  
Author(s):  
Christophe Le Tourneau ◽  
Hui K. Gan ◽  
Albiruni R. A. Razak ◽  
Xavier Paoletti

2016 ◽  
Vol 43 (4) ◽  
pp. E153-E160 ◽  
Author(s):  
Denise Weiss ◽  
Laurel Northouse ◽  
Sonia Duffy ◽  
Berit Ingersoll-Dayton ◽  
Maria Katapodi ◽  
...  

Author(s):  
Pavel Mozgunov ◽  
Rochelle Knight ◽  
Helen Barnett ◽  
Thomas Jaki

There is growing interest in Phase I dose-finding studies studying several doses of more than one agent simultaneously. A number of combination dose-finding designs were recently proposed to guide escalation/de-escalation decisions during the trials. The majority of these proposals are model-based: a parametric combination-toxicity relationship is fitted as data accumulates. Various parameter shapes were considered but the unifying theme for many of these is that typically between 4 and 6 parameters are to be estimated. While more parameters allow for more flexible modelling of the combination-toxicity relationship, this is a challenging estimation problem given the typically small sample size in Phase I trials of between 20 and 60 patients. These concerns gave raise to an ongoing debate whether including more parameters into combination-toxicity model leads to more accurate combination selection. In this work, we extensively study two variants of a 4-parameter logistic model with reduced number of parameters to investigate the effect of modelling assumptions. A framework to calibrate the prior distributions for a given parametric model is proposed to allow for fair comparisons. Via a comprehensive simulation study, we have found that the inclusion of the interaction parameter between two compounds does not provide any benefit in terms of the accuracy of selection, on average, but is found to result in fewer patients allocated to the target combination during the trial.


Sign in / Sign up

Export Citation Format

Share Document